<DOC>
	<DOCNO>NCT00431496</DOCNO>
	<brief_summary>The purpose study show use cinacalcet patient End Stage Renal Disease help achieve NKF K/DOQI target serum calcium calcium phosphorous product .</brief_summary>
	<brief_title>A Study Cinacalcet Improve Achievement National Kidney Foundation Kidney Disease Outcomes Quality Initiative ( K/DOQI ) Targets Patients With End Stage Renal Disease ( ESRD )</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism , Secondary</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Cinacalcet Hydrochloride</mesh_term>
	<criteria>Patients ESRD require maintenance dialysis ( haemodialysis , haemodiafiltration , haemofiltration , peritoneal dialysis ) least 1 month Being treat Aranesp anaemia management stabilise haemoglobin ( Hb ) level . Hb stabilisation define two consecutive Hb measurement screen period ( must include recent assessment ) 110 g/L . Males females &gt; 18 year age time informed consent Patients participate study must agree use , opinion principal investigator , highly effective contraceptive measure throughout study . Females must negative serum pregnancy test within 21 day day 1 childbearing potential The mean 2 Intact parathyroid hormone ( iPTH ) determination within 21 day study day 1 drawn least 2 day apart must &gt; 31.8 pmol/L ( 300 pg/mL ) &lt; 84.8 pmol/L ( 800 pg/mL ) The mean 2 serum calcium determination ( correct albumin ) drawn day PTH determination must &gt; 2.1 mmol/L ( 8.4 mg/dL ) Signed Independent Ethics Committee ( IEC ) approve Informed Consent document , ANY study specific procedure initiate Have receive vitamin D therapy le 21 day day 1 require change prescribe vitamin D brand dose within 21 day day 1 . If patient prescribe vitamin D therapy , must remain free vitamin D therapy 21 day day 1 Have unstable medical condition , define hospitalise , dialysis vascular access revision , within 30 day day 1 , otherwise unstable judgment investigator Hypersensitivity Sensipar component Are currently breastfeed Have parathyroidectomy 3 month day 1 Experienced myocardial infarction within 3 month prior day 1 Have red blood cell transfusion within 3 month prior day 1 Are currently enrol , yet complete least 30 day day 1 invasive investigational device investigational drug trial , receive investigational agent ( experimental dialysis machine acceptable ) Have gastrointestinal disorder may associate impaired absorption orally administer medication inability swallow tablet Have disorder would interfere understand give informed consent , compliance protocol requirement Have previously enrol study participate trial Sensipar</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Anemia</keyword>
	<keyword>Intact Parathyroid Hormone ( iPTH )</keyword>
	<keyword>Secondary Hyperparathyroidism ( SHPT )</keyword>
</DOC>